| Damen Wayne Hershberger, MD | |
|
9300 E 29th St N Ste 320, Wichita, KS 67226-2184 | |
| (316) 858-7100 | |
| (316) 858-7103 |
| Full Name | Damen Wayne Hershberger |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 13 Years |
| Location | 9300 E 29th St N Ste 320, Wichita, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023308939 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 0437436 (Kansas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pearl Ob/gyn, Llc | 4880097898 | 4 |
News Archive
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.
A new study, published on the medRxiv* preprint server, suggested that selective pressures induced by the administration of monoclonal antibodies (Bamlanivimab) may require increased genomic surveillance to identify and control the spread of therapy-induced variants.
Researchers at Ben-Gurion University of the Negev have developed an innovative anti-biofilm coating, which has significant anti-adhesive potential for a variety of medical and industrial applications.
The U.S. Food and Drug Administration today approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.
› Verified 9 days ago
| Entity Name | Heartland Women's Group At Wesley Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568774297 PECOS PAC ID: 5698968881 Enrollment ID: O20101020000755 |
News Archive
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.
A new study, published on the medRxiv* preprint server, suggested that selective pressures induced by the administration of monoclonal antibodies (Bamlanivimab) may require increased genomic surveillance to identify and control the spread of therapy-induced variants.
Researchers at Ben-Gurion University of the Negev have developed an innovative anti-biofilm coating, which has significant anti-adhesive potential for a variety of medical and industrial applications.
The U.S. Food and Drug Administration today approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.
› Verified 9 days ago
| Entity Name | Wesley Physicians Medical Specialties Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699069732 PECOS PAC ID: 1355509886 Enrollment ID: O20120229000737 |
News Archive
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.
A new study, published on the medRxiv* preprint server, suggested that selective pressures induced by the administration of monoclonal antibodies (Bamlanivimab) may require increased genomic surveillance to identify and control the spread of therapy-induced variants.
Researchers at Ben-Gurion University of the Negev have developed an innovative anti-biofilm coating, which has significant anti-adhesive potential for a variety of medical and industrial applications.
The U.S. Food and Drug Administration today approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.
› Verified 9 days ago
| Entity Name | Pearl Ob/gyn, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659949931 PECOS PAC ID: 4880097898 Enrollment ID: O20210728003731 |
News Archive
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.
A new study, published on the medRxiv* preprint server, suggested that selective pressures induced by the administration of monoclonal antibodies (Bamlanivimab) may require increased genomic surveillance to identify and control the spread of therapy-induced variants.
Researchers at Ben-Gurion University of the Negev have developed an innovative anti-biofilm coating, which has significant anti-adhesive potential for a variety of medical and industrial applications.
The U.S. Food and Drug Administration today approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.
› Verified 9 days ago
| Entity Name | Pearl Girl Clinics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376228049 PECOS PAC ID: 6406210921 Enrollment ID: O20230915001741 |
News Archive
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.
A new study, published on the medRxiv* preprint server, suggested that selective pressures induced by the administration of monoclonal antibodies (Bamlanivimab) may require increased genomic surveillance to identify and control the spread of therapy-induced variants.
Researchers at Ben-Gurion University of the Negev have developed an innovative anti-biofilm coating, which has significant anti-adhesive potential for a variety of medical and industrial applications.
The U.S. Food and Drug Administration today approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Damen Wayne Hershberger, MD 4900 S Monaco St Ste 210, Suite 301, Denver, CO 80237-3487 Ph: (316) 858-7100 | Damen Wayne Hershberger, MD 9300 E 29th St N Ste 320, Wichita, KS 67226-2184 Ph: (316) 858-7100 |
News Archive
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.
A new study, published on the medRxiv* preprint server, suggested that selective pressures induced by the administration of monoclonal antibodies (Bamlanivimab) may require increased genomic surveillance to identify and control the spread of therapy-induced variants.
Researchers at Ben-Gurion University of the Negev have developed an innovative anti-biofilm coating, which has significant anti-adhesive potential for a variety of medical and industrial applications.
The U.S. Food and Drug Administration today approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.
› Verified 9 days ago
Edmond G Feuille Ii, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 551 N Hillside St, Ste 510, Wichita, KS 67214 Phone: 316-685-0559 Fax: 316-685-0455 | |
Dr. Elizabeth Carole Melton-mendoza, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1010 N Kansas St, Wichita, KS 67214 Phone: 316-962-3100 | |
Mackenzie Dikeman, Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1010 N Kansas St Ste 3023, Wichita, KS 67214 Phone: 316-293-2665 | |
Lucy Lehoczky, Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1010 N Kansas St Ste 3023, Wichita, KS 67214 Phone: 316-293-2665 | |
Andrea Marie Fullerton, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1515 S Clifton, Ste 400, Wichita, KS 67208 Phone: 316-636-1550 Fax: 316-689-9769 | |
Dr. Thalia J Lopez, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 527 N Grove St, Wichita, KS 67214 Phone: 316-262-2415 Fax: 316-264-4734 |